
# Plaque Psoriasis High Cost Immune Modulator Treatment Pathway

Approved by Surrey Heartlands Integrated Care System Area Prescribing Committee October 2023



	Definition	Action
Primary Failure	Occurs when the response criteria (as defined within the NICE TA) is <b>not</b> <b>fully met</b> when response to treatment is assessed at the time interval defined within the NICE TA	Move to the NEXT treatment line/mode of action (if one is available)
Secondary Failure	Occurs when the response to treatment (as defined within the NICE TA) is	Move to the NEXT treatment line/mode of action
	no longer met	(if one is available)
Primary intolerance/adverse effects	An occurrence that causes discontinuation of treatment, due to inability to	
	tolerate side-effects of that treatment that occurs during the initial time	Use another option from the SAME treatment line
	period defined by the NICE TA	
Secondary intolerance/adverse effects	An occurrence that causes discontinuation of treatment, due to inability to	Move to the NEXT treatment line OR discuss at
	tolerate side effects of that treatment that occurs after the initial time	
	period defined by the NICE TA	Dermatology Clinical Network.
Conception	If conception plans or pregnancy indicate a change of drug is advisable,	Diasco undato Divotos accordingly
	it is agreed that this does not constitute a change in line of treatment	Please update Blueteq accordingly

### Initiate treatment at 1st line with the least costly treatment option which currently is Biosimilar adalimumab. (treatments highlighted are the least costly preparation in class)

Mode of action (Note: different colour denotes oral or subcu- taneous treatment)	Drug	NICE TA & date of publication	Expected clinical re- view below and then every 6 months:	Points to consider when initiating
Fumaric Acid ester	Dimethyl Fumarate (ORAL)	NICE TA475	16 weeks	www.nice.org.uk_Place in therapy as an alternative to biological therapies and apremilast
Phosphodiesterase (PDE4) inhibitor	Apremilast (ORAL)	NICE TA419	16 weeks	www.nice.org.uk Apremilast was less effective but also less costly than biological therapies.
TYK2 enzyme (TYK2 belongs to the JAK family) NHS resources- Information from Bristol Myers Squibb (NICE committee papers) As a small molecule medication, it is anticipat- ed that deucravacitinib will not develop immu- nogenicity and it therefore presents patients with an option for a treatment with good durability and less need for switching.	Deucravacitinib (ORAL)	NICE TA907	24 weeks	www.medicines.org.uk It is not known whether TYK2 inhibition may be associated with the adverse reactions of JAK inhibition. www.nice.org.uk Clinical effectiveness: Less effective and more expensive than adalimumab, bimekizumab and til- drakizumab. Clinical trial evidence shows that deu- cravacitinib improves symptoms of plaque psoriasis com- pared with placebo and apremilast.
TNF alpha inhibitor	Adalimumab	NICE TA146	16 weeks	Adalimumab is the least costly systemic biologic treatment available (August 2023)
<ul> <li>Adalimumab is the least costly TNF alpha inhibitor</li> </ul>	Etanercept	NICE TA103	12 weeks	Biosimilars available
<ul> <li>Note that by using SC infliximab ad- ministration costs will be reduced and capacity released in infusion suites</li> </ul>	Infliximab	NICE TA134	10 weeks	IV biosimilars available Subcutaneous (SC) biosimilar available SC injection licensed for use in Psoriasis. Consider SC route over Infusion to release capacity in infusion suites
	Certolizumab	NICE TA574	16 weeks	In conception or pregnancy if change of drug is advisable, this does not constitute a change in line of treatment.
Interleukin 17A/RA inhibitor	Secukinumab	NICE TA350	12 weeks	www.nice.org.uk Clinical effectiveness: Secukinumab appears to be more clinically effective than etanercept and adalimumab, and to have similar clinical effectiveness to ustekinumab and infliximab, the only direct trial evidence was for secukinumab compared with etanercept. NB: 2 x 150mg (300mg) injections required for each dose
	Ixekizumab	NICE TA442	12 weeks	www.nice.org.uk Clinical effectiveness: Direct trial evi- dence was for ixekizumab compared with etanercept.
	Brodalumab	NICE TA511	12 weeks	www.nice.org.uk Clinical effectiveness: The committee concluded that brodalumab was more clinically effective than placebo and ustekinumab.
	Bimekizumab	NICE TA723	16 weeks	www.nice.org.uk Clinical effectiveness: Results of trials showed that bimekizumab was more effective than ada- limumab, secukinumab and ustekinumab. NB: 2 x 160mg (320mg) injections required for each dose
Interleukin (IL)23 protein	Tildrakizumab	NICE TA575	12-28 weeks then at 28 weeks	www.nice.org.uk Clinical effectiveness: NICE concluded that tildrakizumab was more clinically effective than place- bo and etanercept www.nice.org.uk & www.medicines.org.uk In patients with certain characteristics (e.g. high disease burden, body weight ≥ 90 kg) 200 mg may provide greater efficacy.
	Risankizumab	NICE TA596	12 weeks	www.nice.org.uk Clinical effectiveness: Evidence from clinical trials shows that risankizumab is more effective than adalimumab and ustekinumab.
	Guselkumab	NICE TA521	16 weeks	www.nice.org.uk Clinical effectiveness: Evidence from clinical trials and indirect comparisons show that guselku- mab is more effective than TNF-alpha inhibitors (that is, adalimumab, etanercept and infliximab) and ustekinumab. It also suggests that guselkumab is likely to provide similar health benefits to ixekizumab and secukinumab.
Interleukin 12/23 inhibitor	Ustekinumab	NICE TA180	16 weeks	www.nice.org.uk Clinical effectiveness: Demonstrated to be more clinically effective than etanercept

#### **References:**

- 1. 2.
- NICE Technical Appraisals. Available at: <u>www.nice.org.uk</u> Drug Safety Update April 2023. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembo-lism, serious infections and increased mortality. Available at: <u>Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malig-nancy, venous thromboembolism, serious infections and increased mortality</u>

## Clinical contraindications and considerations for pre-biologics <u>www.medicines.org.uk</u> & <u>www.nice.org.uk</u> & Clinical Guideline: Psoriasis (assessment

& management) CG153. (Developed: January 2018 Updated November 2021)

### **Clinical contraindications**

Phototherapy (TLO1 or PUVA)	Ciclosporin	Methotrexate	Acitretin
	<ul> <li>Hypersensitivity to the active substance or to any of the excipients</li> <li>Combination with products containing Hypericum perforatum (St John's Wort)</li> <li>Combination with medicines that are substrates for the multidrug efflux transporter P-glycoprotein or the organic anion transporter proteins (OATP) and for which elevated plasma concentrations are associated with serious and/or life-threatening events, e.g. bosentan, dabigatran etexilate and aliskiren</li> </ul>	<ul> <li>Presence of severe/significant renal or significant hepatic impairment.</li> <li>Liver disease including fibrosis, cirrhosis, recent or active hepatitis; active infectious disease; and overt or laboratory evidence of immunodeficiency syndrome(s).</li> <li>Serious cases of anaemia, leucopenia or thrombocytopenia.</li> <li>Methotrexate should not be used concomitantly with drugs with antifolate properties (eg co- trimoxazole).</li> <li>Methotrexate is teratogenic and should not be given during pregnancy or to mothers who are breast feeding.</li> <li>Patients with a known allergic hypersensitivity to methotrexate should not receive methotrexate</li> </ul>	<ul> <li>PREGNANCY: Acitretin, the active substance of Acitretin, is highly teratogenic and must not be used during pregnancy. The same applies to all women of childbearing potential, unless strict contraception is practiced 4 weeks before, during and for 3 years after treatment</li> <li>LACTATION: Acitretin is contraindicated during the period of breast-feeding.</li> <li>Acitretin is not indicated in hepatic and renal dysfunction (liver and kidney failure), severe hyperlipaemia, concurrent use of vitamin A or other retinoids and during co-medication with methotrexate. Since Acitretin and tetracyclines can cause an increase in intracranial pressure, they must not be given concurrently.</li> <li>Acitretin must not be used concomitantly with low dose progesterone-only products (minipills)</li> <li>Acitretin must not be used in patients with hypersensitivity to the active substance "acitretin" or other retinoids or to any of the excipients.</li> </ul>

#### Cautions

Phototherapy (TLO1 or PUVA)	Ciclosporin	<u>Methotrexate</u>	Acitretin
<ul> <li>People at risk of skin cancer</li> <li>People with lighter skin types I or II on Fitzpatrick Scale</li> </ul>	<ul> <li>Lymphomas or other malignancies</li> <li>Related to degree and duration of immunosuppression</li> <li>Excess unprotected sun exposure</li> <li>Concomitant UVB/PUVA not recommended</li> <li>Infections</li> <li>Short-term reversible, dose reduction</li> <li>Long-term – Structural changes</li> <li>Hepatotoxicity</li> <li>Dose-dependent, reversible</li> <li>Hypertension, blood lipids increased, hyperkalaemia, hypomagnesaemia, hyperuricaemia.</li> </ul>	<ul> <li>Acute or chronic interstitial pneumonitis</li> <li>Blood dyscrasia (leucopenia, thrombocytopenia)</li> <li>Hepatotoxicity – risk factors</li> <li>Alcohol abuse</li> <li>Increased LFTs</li> <li>Hereditary hepatopathy</li> <li>Diabetes Mellitus</li> <li>Adiposity</li> <li>Exposure to hepatotoxic drugs</li> <li>Diarrhoea, ulcerative stomatitis with risk of haemorrhagic enteritis and intestinal perforation (death)</li> <li>Decreased fertility</li> <li>Inactive chronic infections</li> <li>Pleural effusions, ascites</li> </ul>	

**Other considerations for phototherapy:** \* Physical limitations – patients cannot stand for treatment

- \*Severe psoriasis that won't respond—pustular & erythrodermic presentations
- \* Position of disease—scalp, flex joints, lower leg, nail
- \* Manifestation of disease—thick plaques